Page last updated: 2024-10-22

amitriptyline and Scleroderma, Systemic

amitriptyline has been researched along with Scleroderma, Systemic in 1 studies

Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.

Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bondavalli, P1
Parodi, A1
Rebora, A1

Other Studies

1 other study available for amitriptyline and Scleroderma, Systemic

ArticleYear
Peripheral neuropathy in scleroderma successfully treated with amitriptyline.
    International journal of dermatology, 1997, Volume: 36, Issue:3

    Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Female; Humans; Middle Aged; Peripheral Nervous Sys

1997